Ugur Sahin
MD
Co-Founder and CEO
👥Biography 个人简介
Ugur Sahin co-founded BioNTech and has been the driving force behind mRNA cancer vaccine development, including personalized neoantigen-based mRNA vaccines. His laboratory pioneered the BNT111 (melanoma TAA vaccine) and BNT113 (HPV-positive head and neck cancer) programs that have shown clinical activity in combination with pembrolizumab. He developed the framework for individualized mRNA vaccines manufactured from patient tumor sequencing data within weeks. His work represents the convergence of cancer genomics, immune oncology, and mRNA medicine.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ugur Sahin 的研究动态
Follow Ugur Sahin's research updates
留下邮箱，当我们发布与 Ugur Sahin（BioNTech SE）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment